Transaction Information
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced the closing of its underwritten public offering for gross proceeds of $12.4 million.
The Company issued 4,238,906 shares of common stock and warrants to purchase up to 4,238,906 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock at a combined public offering price of $2.93 per share. The warrants have an exercise price of $2.93 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The warrants are fixed priced and do not contain any price based anti-dilution or variable pricing features.
Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering.
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. For more information, visit http://www.https://windtreetx.com/.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.